

Artin Minaeian, M.D.

artin.minaeian@gmail.com

Office Phone: 818-265-2245

Fax: 877-575-9782

1451 E. Chevy Chase Dr.

Suite 201

Glendale, CA 91207

Work Experience

- SC3 Research - Pasadena, Principal Investigator
 - Pasadena, CA
 - 2019 – Present
- AXON Neurology, CEO/Founder. Outpatient Neurology practice
 - Glendale, CA
 - 2017-Current
- Artin Minaeian M.D. Inc, CEO/Founder. Inpatient and Outpatient Private Neurology Practice
 - Glendale, CA
 - 2017-Current
- Southern California Neurology Consultants
 - Glendale, CA
 - September 2015-2017
- SAGE Neurohospitalist Group
 - September 2015-2017
- Clinical Instructor of General and Vascular Neurology
 - Jamaica Hospital Medical Center
 - July 2014-July 2015
- Staff Neurologist
 - Medisys Health Care System
 - July 2014-2015

Hospital Affiliations

- Glendale Adventist Medical Center, Glendale, CA, 2015-current
- Glendale Memorial Hospital, Dignity Health, Glendale, CA, 2015-current
- USC Verdugo Hills Hospital, Glendale, CA, 2016-current
- Huntington Memorial Hospital, Pasadena, CA, 2015-2018

Education

Fellowship

University of Massachusetts, Worcester MA

07/01/2013-06/30/2014

Vascular Neurology/Stroke

Residency

New York Medical College at Westchester Medical Center, Valhalla NY
07/01/2010-06/30/2013
Neurology Resident PGY 2-4

Mt. Sinai School of Medicine at Elmhurst Hospital, Elmhurst NY
07/01/2009-06/30/2010
Preliminary Internal Medicine PGY-1

Medical School

St. George's University School of Medicine, Grenada, West Indies
01/01/2005-05/08/2009

Undergraduate

University of California Irvine, Irvine CA
01/01/2002-06/15/2004
Bachelor of Science in Biological Sciences, Class of 2004
Dean's List 5 Quarters

Glendale Community College
07/01/1999-12/31/2001
Biology Major

High School

Glendale High School
Graduated June 1999
High School Diploma

Teaching Experience:

1. Clinical instructor at USC/Verdugo Hills Hospital
2. Clinical instructor of Neurology: New York Medical College
3. Clinical Instructor of Neurology: Jamaica Hospital Medical Center

Licensure

- 1) California: Full
Certification Date: 04/24/2015-Current, Active
License No.: A135849
- 2) New York State: Full but Inactive
Certification Date: 3/31/2014-3/31/2016, Inactive License
No.: 274513
- 3) Commonwealth of Pennsylvania: Full but Inactive
Certification Date: 08/21/2013-12/31/2014, Inactive
License No.: MD449916
- 4) Commonwealth of Massachusetts: Limited/Training/Inactive
Certification Date: 06/19/2013-06/30/2014
License No.: 256801

National/ International Clinical Trials Participation:

1. BRAINSGATE/INTERACT, Sub-I
2. SWIFT PRIME, Residency
3. POINT, Residency
4. ID-DEF, Sub-I
5. GAMES, Sub-I
6. A Phase III, Prospective Double-Blind, Randomized, Placebo-controlled trial of Thrombolysis in Imaging-eligible, Late-window patients to Assess the Efficacy and Safety of Tenecteplase (Timeless), Genentech, Inc.
7. A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
8. 1820203: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury (JUNIPER). Role: Sub-Investigator
9. 20180060: Effect of Erenumab on Disability and Work Productivity in Employed Subjects With Episodic Migraine Who Have Previously Failed 1 or More Migraine Preventive Treatments. Role: Sub-Investigator
10. ADX-48621-301: Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medication. Role: Sub-Investigator
11. BN40423: A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease. Role: Sub-Investigator
12. BN40955: An Open-label extension study to Evaluate the Long-term Safety and Tolerability of Intrathecally administered RO7234292 (RG6042) in patients with Huntington's Disease. Role: Sub-Investigator
13. CVL-751-PD-001: A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, 27 Week Study of the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease. Role: Sub-Investigator
14. CVL-75 I- PD-003: A Phase 3, Double-Blind, Randomized, Placebo-Controlled., Parallel Group, Flexible-Dose, 27 Week Study of the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy in Levodopa Treated Subjects With Parkinson's Disease With Motor Fluctuations. Role: Sub-Investigator
15. CVN424-201: A Phase II, Randomized., Double-Blind, Placebo-Controlled., Multicenter Study of CVN424 in Parkinson's Disease Patients with Motor Fluctuations. Role: Sub-Investigator
16. EFC16034: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 2). Role: Sub-Investigator
17. EFC16035: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS). Role: Sub-Investigator
18. EFC16445: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with non-relapsing secondary progressive multiple sclerosis (HERCULES). Role: Sub-Investigator
19. ENT-01-030: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET). Role: Sub-Investigator
20. ENT-01 -2b-20-02: A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients with Parkinson's disease and Constipation over a 14-week Period. Role: Sub-Investigator
21. ION-682884-CS3: A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Role: Sub-Investigator
22. M15-736: A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's

- Disease Patients. Role: Sub-Investigator
23. MPIGADP3-GADPT3: A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo-controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long-acting IM injection of glatiramer acetate, administered once every four weeks. Role: Sub-Investigator
 24. MS200527_0080: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. Role: Sub-Investigator
 25. OBS16136: A Validation Study to Assess the Validity, Measurement Responsiveness, & Reliability of the Parkinson's Disease Functional Impacts Digital Instrument (PD-FIDI) in Patients with Parkinson's Disease (PD) with or without Glucocerebrosidase (GBA) Mutations. Role: Sub-Investigator
 26. CBAF312AUS02: A Study of the safety and tolerability dose titrated Oral Siponimod in patients with relapsing forms of multiple sclerosis. Role: Sub-Investigator
 27. I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease. Role: Principal Investigator
 28. WA40404: A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis. Role: Sub-Investigator
 29. BK-JM-201: A Randomized, Double-Blind, Placebo-Controlled, Two-part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety and Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components. Role: Principal Investigator
 30. ALZ-801: A Phase 2, Single-arm Study of the Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease Who Are Carriers of the $\epsilon 4$ Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4). Role: Principal Investigator
 31. BHV4157-203. A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease. Role: Sub-Investigator
 32. GN41851. A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Adult Patients With Relapsing Multiple Sclerosis. Role: Sub-Investigator
 33. NLY-01-PD-1. Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease. Role: Sub-Investigator
 34. M20-098. Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease. Role: Sub-Investigator

Publications

Completed:

- 1) Emergency Department Length of Stay and Outcome after Ischemic Stroke. Minaeian A, Patel A, Essa B, Goddeau RP Jr, Moonis M, Henninger N. J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2167-2173. doi: 10.1016/j.jstrokecerebrovasdis.2017.04.040. Epub 2017 May 24.
- 2) Mechanical Thrombectomy in Wake-Up Strokes: A Case Series Using Alberta Stroke Program Early CT Score (ASPECTS) for Patient Selection. Konstas AA, Artin Minaeian, Ross IB., 2017
- 3) Clinical impact of leukoaraiosis burden and chronological age on neurological deficit recovery and 90-day outcome after minor ischemic stroke. Onteddu, SR, Goddeau RP Jr, Artin Minaeian, Henninger N. 2015
- 4) Does Emergency Department length of stay affect the 90-day functional outcome after acute ischemic stroke? Anand Patel, Artin Minaeian, Ajay Tunguturi, Richard Godd, Nils Henninger, 2015
- 5) Leukoaraiosis is associated with impaired functional recovery and outcome after mild ischemic stroke, Sanjeeva Onteddu MD, Artin Minaeian MD, Richard Goddeau MD, Nils Henninger MD, 2014
- 6) Incidence and Outcome from Procedural Distal Emboli during Penumbra Thrombectomy for Acute Stroke, Akira Todo, MD; Artin Minaeian MD, Ramandeep Sahni, MD; Stephen Marks MD, Brij Singh Ahluwalia MD, and Kuo H Chao, MD, MPH. J Neurointerv Surg. 2013 Mar;5(2):135-8. doi: 10.1136/neurintsurg-2011-010216. Epub 2012 Feb 13.

- 7) Interferon Alpha Receptor Cleavage by TACE and Gamma Secretase, Artin Minaeian, Dr. John J. Krolewski. Journal of Undergraduate Research in the Biological Sciences. Summer 2004, Irvine, CA.

In Progress:

- 1) Locus Minoris Phenomena, Artin Minaeian MD, Sanjeeva Onteddu MD, Nils Henninger MD, Richard Goddeau MD
- 2) Coexistence of multiple non-inflammatory intracranial, extracranial, pancreaticoduodenal, anterior spinal artery aneurysms, Artin Minaeian MD, Neetu Dhadwal MD, Brij Ahluwalia Singh MD, in Progress. Abstract/poster presentation at AAN 2013 in San Diego, CA.
- 3) Endovascular Management of Embolic Stroke Resulting from Cervical Spine Osteochondroma, Case Report; Artin Minaeian M.D., Ramandeep Sahni M.D., Brij Ahluwalia Singh M.D., Akira Todo M.D., John Gillick M.D., Kiran Patil M.D, Stephen Marks M.D., Michael F. Stiefel M.D. PhD, publication in progress. Abstract/Poster presented at the First International Conference of Interventional Neurology at Minneapolis, MN.
- 4) EEG Long Term Monitoring in ICU Setting, Venket Ramani MD, Artin Minaeian MD, Westchester Medical Center. 09-2010-current. In progress, Data Collection
- 5) Application of the DRAGON Score to Predict Outcome Following Endovascular Stroke Treatment. Todo A, Shah SO, Minaeian A, Marks SJ, Ahluwalia, BS, Stiefel MF. Presented at 2012 Neurocritical Care Society Meeting
- 6) Application of the CRASH Score When Using Intracranial Multimodality Monitoring. Shah SO, Minaeian A, Javed S, Marini C, Stiefel MF. Accepted to American Association of Surgery for Trauma 2013

Certifications

- Neurology Board Certified, Valid Until 9/25/2024, Certification #: 58915
- Vascular Neurology Board Certified, Valid Until 10/24/2026, Certification#: 1468
- Good Clinical Practice Certified, Valid Until 05/18/2023, Record ID: 40824116
- DEA: FM 4548030, New York State, Expiration 1/31/2017
- NPI: 1013356344
- EC FM G Certified: 0-720-538-8, issued on 5/28/2009
- Chief Resident at NYMC, July 2012- June 2013 Allergan Epic Injection Training, July 2016
- Allergan Juvedern Voluma XC certificate of completion
- Allergan Kybella certificate of completion
- USMLE Step I, TI and III: Passed
- Basic Life Support Certificate (BLS), recertified June 2013
- Advanced Cardiac Life Support (ACLS), recertified June 2013
- Occupational Safety and Health Administration (OSHA)- December 2006
- Trauma Evaluation And Management (TEAM)- December 2006
- Phlebotomy (SGU Emergency Medicine Club) - December 2006
- Health Insurance Portability & Accountability Act certificate (HIPAA)- December 2006

Biographic Data

Date of birth: December 23, 1980
Ethnicity: Armenian
Place of birth: Tehran, Iran
Places Lived: Iran (16 years), Spain (1 year), United States (Since 1997)
Marital Status: Married
Citizenship: United States

Experience

- **Grand Rounds Presentation**, Dignity Health, Glendale Memorial Hospital 2017
- **Grand Rounds Presentation**, Adventist Health, Glendale, 2017, 2018
- **Grand Rounds Presentation**, USC, Verdugo Hills Hospital, 2019
- **Grand Rounds Presentation**, Citrus Valley Medical Center, November 2015, 2016
- **Grand Rounds Presentation**, Glendale Memorial Hospital, 2015, 2016
- **Grand Rounds Presentation on most current Ischemic Stroke Guidelines**, Jamaica Hospital Medical Center, May 2015
- **American Academy of Neurology Advocacy in Washington DC, "Neurology on the Hill"**, Selected to be partaking in current policy issues. Attended in March, 2014 and again March 2015
- **On Stage presentation at the First International Congress of Interventional Neurology**, held in Minneapolis, Minnesota in October 2011 (CME)
- **Blood Pressure Management in Strokes, Grand Rounds, University of Massachusetts**, May 2014
- **Poster Presentation at the 2014 American Academy of Neurology**: Leukoaraiosis is associated with impaired functional recovery and outcome after mild ischemic stroke
- **On stage presentation at the First International Congress of Interventional Neurology**, held in Minneapolis, Minnesota in October 2011 (CME): presented on stage case report
- **Poster Presentation at the 2013 American Academy of Neurology**: Coexistence of Multiple Non-inflammatory, Intracranial, Extracranial, Pancreaticoduodenal and Anterior Spinal Artery Aneurysms
- **Selective Service in Prague, Czech Republic**, rotated at various medical facilities of Prague, Czech Republic with intention of familiarizing with European management of diseases.
- **Clinical Care Extender Volunteering Program**, at Hoag Hospital, in Newport Beach CA. Member of the board in organization of the program
- **Research Assistant**, Pathology Research Center, University of California Irvine, School of Medicine. Sept. 2002-June 2004. Performed PCRs, Western Blots, electrophoresis, and mice dissections.
- **Research Assistant**, Department of Cell Biology, University of California Irvine. Sept. 2003- June 2004. Protein Crystallization. Assisted in purifying proteins.

Memberships and Affiliations

- **Political Action Committee of American Academy of Neurology**, February 2011- Current. Key contact and contributor
- **American Academy of Neurology**, January 2011- Current
- **American Medical Student Association**, 2005-current. Participated in community health fairs.
- **St. George's University Emergency Medicine Club**, March 2005- Dec. 2006. Participated in various medical workshops.
- **St. George's University Surgery Club**, March 2005- Dec. 2006. Participated in various medical workshops.

Languages:

- English: Read, write, speak fluently
- Farsi: Read, write, speak fluently

- Armenian: Read, write, speak fluently
- Spanish - Read, write, speak moderately

References:

- Furnished upon Request